WO2024135675A1 - Composition contre le virus de la grippe pour la gorge et agent anti-virus de la grippe pour la gorge - Google Patents

Composition contre le virus de la grippe pour la gorge et agent anti-virus de la grippe pour la gorge Download PDF

Info

Publication number
WO2024135675A1
WO2024135675A1 PCT/JP2023/045484 JP2023045484W WO2024135675A1 WO 2024135675 A1 WO2024135675 A1 WO 2024135675A1 JP 2023045484 W JP2023045484 W JP 2023045484W WO 2024135675 A1 WO2024135675 A1 WO 2024135675A1
Authority
WO
WIPO (PCT)
Prior art keywords
test
virus
influenza virus
throat
cetylpyridinium chloride
Prior art date
Application number
PCT/JP2023/045484
Other languages
English (en)
Japanese (ja)
Inventor
陽比古 小峰
奈子 岡本
Original Assignee
サンスター株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンスター株式会社 filed Critical サンスター株式会社
Publication of WO2024135675A1 publication Critical patent/WO2024135675A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to an anti-influenza virus composition for the throat and an anti-influenza virus agent for the throat.
  • Patent Document 1 discloses an invention relating to an oral composition that contains 0.001 to 5% by weight of cetylpyridinium chloride and 0.0002 to 0.3% by weight of a chlorhexidine derivative.
  • cetylpyridinium chloride has a certain degree of antiviral activity when it is in contact with viruses for a long period of time, such as several tens of minutes.
  • cetylpyridinium chloride has a certain degree of antiviral activity when it is in contact with viruses for a long period of time, such as several tens of minutes.
  • the anti-influenza virus throat composition of the present invention contains at least one selected from isoprene, geraniol, menthol, limonene, thymol, cineol, bisabolol, borneol, camphor, and glycyrrhizin, and a quaternary ammonium salt as active ingredients.
  • the quaternary ammonium salt preferably contains at least one selected from cetylpyridinium chloride and benzalkonium chloride.
  • the anti-influenza virus agent for the throat of the present invention contains at least one selected from isoprene, geraniol, menthol, limonene, thymol, cineol, bisabolol, borneol, camphor, and glycyrrhizin, and a quaternary ammonium salt as active ingredients.
  • the quaternary ammonium salt contains at least one selected from cetylpyridinium chloride and benzalkonium chloride.
  • the anti-influenza virus throat composition or anti-influenza virus agent of the present invention can exert an anti-influenza virus effect in the throat.
  • FIG. 1 is a diagram illustrating the results of an anti-influenza A virus test of a composition containing cetylpyridinium chloride and various terpenes.
  • FIG. 1 is a diagram illustrating the results of an anti-influenza A virus test of a composition containing cetylpyridinium chloride and glycyrrhizin.
  • FIG. 1 illustrates the results of an anti-influenza B virus test of a composition containing cetylpyridinium chloride and thymol.
  • FIG. 1 is a diagram illustrating the results of an anti-herpes virus test of a composition containing cetylpyridinium chloride and glycyrrhizin.
  • FIG. 1 is a diagram illustrating the results of an anti-feline calicivirus test of a composition containing cetylpyridinium chloride and various terpenes.
  • FIG. 1 is a diagram illustrating the results of an anti-adenovirus test of a composition containing cetylpyridinium chloride and glycyrrhizin.
  • FIG. 1 is a diagram illustrating the results of an anti-type influenza A virus test of a composition containing benzalkonium chloride and various terpenes.
  • the anti-influenza virus composition for throat and the anti-influenza virus agent for throat of the present embodiment contain a quaternary ammonium salt and a terpene as active ingredients.
  • the anti-influenza virus composition for throat and the anti-influenza virus agent for throat may be simply referred to as an anti-virus composition.
  • Quaternary ammonium salts are well-known components widely known as antibacterial agents.
  • the type of quaternary ammonium salt used in the antiviral composition of the present embodiment is not particularly limited.
  • quaternary ammonium salts may be used alone or in combination of two or more. These compounds may also be used in the form of a hydrate, such as a hydrate of cetylpyridinium chloride.
  • the quaternary ammonium salt preferably contains at least one selected from cetylpyridinium chloride and benzalkonium chloride.
  • Cetylpyridinium chloride is a known quaternary ammonium salt generally known as an antibacterial agent. Cetylpyridinium chloride may be used in the form of a hydrate.
  • the content of the quaternary ammonium salt in the antiviral composition may be appropriately set according to the type and/or content of the terpene used in combination, the form of use of the antiviral composition, etc. For example, in the antiviral composition, it is preferably more than 0.05% by mass and 1% by mass or less, more preferably more than 0.05% by mass and 0.5% by mass or less, and even more preferably more than 0.05% by mass and 0.4% by mass or less.
  • the antiviral composition contains a terpene and more than 0.05% by mass of a quaternary ammonium salt, it exerts an antiviral effect against influenza virus.
  • the upper limit or lower limit of the range may be, for example, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.6, 0.7, 0.8, or 0.9% by mass.
  • Terpenes are hydrocarbons whose structural unit is isoprene, and are biological substances produced by plants, insects, fungi, and the like.
  • derivatives having functional groups such as carbonyl groups and hydroxyl groups are called terpenoids.
  • the terpene used in the antiviral composition of this embodiment is at least one selected from isoprene, geraniol, menthol, limonene, thymol, cineol, bisabolol, borneol, camphor, and glycyrrhizin.
  • These terpenes can exert a remarkable anti-influenza virus effect when used in combination with cetylpyridinium chloride.
  • These terpenes may be used alone or in combination of two or more.
  • the content of terpene in the antiviral composition may be appropriately set depending on the type of terpene used, the content of the quaternary ammonium salt used in combination, the form of use of the antiviral composition, etc.
  • the content in the antiviral composition is preferably 0.01 to 1 mass%, more preferably 0.01 to 0.5 mass%, and even more preferably 0.01 to 0.3 mass%.
  • the upper or lower limit of the range may be, for example, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.6, 0.7, 0.8, or 0.9 mass%.
  • a significant anti-influenza virus effect can be exhibited by combining with the quaternary ammonium salt.
  • its content in the antiviral composition is preferably 0.07 to 1 mass%, more preferably 0.07 to 0.5 mass%, and even more preferably 0.07 to 0.3 mass%.
  • the upper or lower limit of the range may be, for example, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.6, 0.7, 0.8, or 0.9 mass%.
  • the antiviral composition of this embodiment may contain components that are commonly used in the art depending on the form of use of the anti-influenza virus agent for the throat, within a range that does not impair the effects of the present invention.
  • examples of such components include preservatives, bactericides, antibacterial agents, anti-inflammatory agents, abrasives, thickeners, humectants, excipients, fragrances, sweeteners, cooling agents, dyes, deodorants, surfactants, solvents, pH adjusters, etc.
  • the form of use of the antiviral composition is not particularly limited, and examples thereof include quasi-drugs, foods, cosmetics, pharmaceuticals, and the like.
  • the antiviral composition When used as an oral composition such as a quasi-drug, it can be applied to oral compositions such as sprays, toothpastes, liquid toothpastes, mouthwashes, and rinses.
  • oral compositions such as sprays, toothpastes, liquid toothpastes, mouthwashes, and rinses.
  • throat compositions and throat preparations that inhibit the infection and proliferation of influenza viruses are preferred.
  • sprays include nasal sprays, throat sprays, and oral sprays.
  • compositions for wiping objects include sprays.
  • the antiviral composition when used as an oral composition such as food, it can be applied to, for example, candies, troches, tablets, gum, granules, powders, jellies, syrups, beverages, etc.
  • the antiviral composition when used as a topical composition such as a cosmetic product, it can be applied to, for example, face packs, pastes, ointments, creams, gels, lotions, emulsions, beauty serums, skin lotions, etc.
  • the antiviral composition When used as a medicine, it can be used, for example, to purify the mouth, cleanse the skin, and keep the skin healthy.
  • the antiviral composition can be used, for example, to suppress or reduce sore throat, swollen throat, throat discomfort, sore throat, or hoarseness caused by throat inflammation.
  • the antiviral composition can be used, for example, to disinfect or clean the skin, hands, mouth, or throat (pharynx).
  • the antiviral composition can also be used, for example, for virus barrier, virus blocking, virus shutting, antivirus, and virus elimination.
  • the antiviral composition is not limited to use on the human body, but can also be used as a liquid agent to be sprayed or applied to products that come into contact with the skin, such as bedding, clothing, furniture, fittings, and other items.
  • Target product materials include, for example, natural fibers, synthetic fibers, natural leather, artificial leather, synthetic leather, wood, synthetic resins, metals, painted surfaces, etc.
  • the antiviral composition contains a quaternary ammonium salt and a terpene as active ingredients.
  • the terpene is at least one selected from isoprene, geraniol, menthol, limonene, thymol, cineol, bisabolol, borneol, camphor, and glycyrrhizin.
  • compositions containing quaternary ammonium salts alone do not exhibit anti-influenza virus effects unless they are in contact with the virus for a long period of time, such as several tens of minutes. It is also known that compositions containing the above-mentioned terpenes alone do not exhibit anti-influenza virus effects.
  • the anti-viral composition of the present invention which contains a combination of a quaternary ammonium salt and the above-mentioned terpenes, exhibits a significant anti-influenza virus effect with a contact time of seconds.
  • Influenza viruses are enveloped viruses that have lipid membranes, so it is speculated that the mechanism of action is that terpenes induce structural changes in the lipid membrane structure, increasing the fluidity of the lipid membrane, making it easier for quaternary ammonium salts to attack the destabilized lipid membrane.
  • the antiviral composition contains at least one selected from isoprene, geraniol, menthol, limonene, thymol, cineol, bisabolol, borneol, camphor, and glycyrrhizin, and a quaternary ammonium salt as active ingredients.
  • the combined use of these terpenes and the quaternary ammonium salt provides a significant anti-influenza virus effect in the throat. These terpenes can enhance the anti-influenza virus effect of the quaternary ammonium salt.
  • a method of using an anti-influenza composition comprising a mixture of at least one selected from isoprene, geraniol, menthol, limonene, thymol, cineol, bisabolol, borneol, camphor, and glycyrrhizin with a quaternary ammonium salt.
  • a method for enhancing the anti-influenza virus effect by mixing at least one selected from isoprene, geraniol, menthol, limonene, thymol, cineol, bisabolol, borneol, camphor, and glycyrrhizin with a quaternary ammonium salt.
  • antiviral composition will be described in more detail with reference to the following examples. Note that the antiviral composition in the examples is a throat preparation, but is not limited to the composition described in the examples section.
  • Example 1 In Example 1, the antiviral effect of a test solution containing cetylpyridinium chloride and various terpenes against influenza A virus was examined.
  • Test Example 1 ⁇ Preparation of test solution as antiviral composition> (Test Example 1-1) 0.3 g of cetylpyridinium chloride, 0.1 g of isoprene stabilized with 4-tert-butylcatechol (TBC), and 10 ml of ethanol were diluted with sterilized ultrapure water to a total weight of 100 g. This was used as the test solution of the antiviral composition of Test Example 1-1 in an anti-type influenza A virus test.
  • TBC 4-tert-butylcatechol
  • Comparative Example 1-1 0.1 g of isoprene stabilized with 4-tert-butylcatechol and 10 ml of ethanol were diluted with sterilized ultrapure water to a total volume of 100 g. This was used as the test liquid of Comparative Example 1-1 and was subjected to an anti-type A influenza virus test.
  • Test Examples 1-2 to 1-11 Comparative Examples 1-2 to 1-11
  • test solutions containing cetylpyridinium chloride, various terpenes shown in Table 1, and ethanol were prepared for Test Examples 1-2 to 1-11.
  • Anti-type A influenza virus test measurement of infectious titer>
  • the anti-type influenza A virus tests for each test liquid of Test Examples 1-1 to 1-11, Comparative Examples 1-1 to 1-11, and Control 1 were performed based on ASTM E1052-20 (ASTM International, 2020) by measuring the virucidal activity against influenza A virus (H1N1).
  • influenza A virus solution was mixed with each test solution in a ratio of 1:9 and allowed to stand at 25°C for 20 seconds to contact the influenza A virus solution with each test solution.
  • the mixture was then neutralized with SCDLP (Soybean-Casein Digest Broth with Lecithin & Polysorbate) medium, and the virus infectivity titer (log 10 [PFU/ml]) against MDCK cells was measured by the plaque method.
  • SCDLP Soybean-Casein Digest Broth with Lecithin & Polysorbate
  • the virus infectivity titer log 10 [PFU/ml] against MDCK cells was measured by the plaque method.
  • Figure 1 the infectivity titer in the test solution of Control 1 is shown by a dotted line.
  • the * mark in Figure 1 indicates that the virus was below the detection limit in the anti-influenza A virus test.
  • the infectious titer was about 1/1000 when combined with cetylpyridinium chloride.
  • the infectious titer was in the range of 1/1000 to 1/100 when cetylpyridinium chloride was used in combination.
  • the infectious titer was in the range of 1/100 to 1/10 when cetylpyridinium chloride was used in combination.
  • the infectious titer was about 1/10 when cetylpyridinium chloride was used in combination.
  • Example 2 In Example 2, the antiviral effect against influenza A virus of test solutions containing glycyrrhizin as a terpene and varying the content of cetylpyridinium chloride was examined.
  • Test Example 2-1 ⁇ Preparation of test solution as antiviral composition> (Test Example 2-1) 0.3 g of cetylpyridinium chloride, 0.1 g of glycyrrhizin stabilized with 4-tert-butylcatechol, and 10 ml of ethanol were diluted with sterilized ultrapure water to a total weight of 100 g. This was used as the test solution of the antiviral composition of Test Example 2-1 in an anti-type influenza A virus test.
  • Test Example 2-2 A test solution of Test Example 2-2 was prepared in the same manner as in Test Example 2-1, except that the amount of cetylpyridinium chloride was 0.05 g.
  • Control 2 Sterile ultrapure water alone was used as the test liquid for Control 2.
  • ⁇ Anti-type A influenza virus test ; measurement of infectious titer> Anti-type influenza A virus tests were performed on each of the test solutions of Test Examples 2-1 to 2-2 and Control 2 in the same manner as in Example 1. The results are shown in Figure 2.
  • the infectious titer in the test solution of Control 2 is shown by a dotted line.
  • the * mark in Figure 2 indicates that the virus was below the detection limit in the anti-type influenza A virus test.
  • Example 3 In Example 3, the antiviral effect of a test solution containing cetylpyridinium chloride and a terpene against influenza B virus was examined.
  • Test Example 3-1 ⁇ Preparation of test solution as antiviral composition> (Test Example 3-1) 0.3 g of cetylpyridinium chloride, 0.1 g of thymol stabilized with 4-tert-butylcatechol, and 10 ml of ethanol were diluted with sterilized ultrapure water to a total weight of 100 g. This was used as the test solution of the antiviral composition of Test Example 3-1 in an anti-type influenza B virus test.
  • Comparative Example 3-1 was prepared as a test solution not containing cetylpyridinium chloride. 0.1 g of thymol stabilized with 4-tert-butylcatechol, 10 ml of ethanol, and sterilized ultrapure water were added to make a total of 100 g to prepare the test solution of Comparative Example 3-1.
  • Comparative Example 3-2 a test solution not containing terpene was prepared. 0.3 g of cetylpyridinium chloride and 10 ml of ethanol were diluted with sterilized ultrapure water to a total volume of 100 g to prepare the test solution of Comparative Example 3-2.
  • test solution of Test Example 3-1 in which terpene (thymol) was used in combination with cetylpyridinium chloride, had a significantly lower infectious titer than the test solution of Comparative Example 3-1.
  • terpene (thymol) was used in combination with cetylpyridinium chloride.
  • the results showed that the combined use of cetylpyridinium chloride and various terpenes also exerted an antiviral effect against influenza B virus. This antiviral effect was equal to or greater than that against influenza A virus.
  • Example 4 the antiviral effect of a test solution containing cetylpyridinium chloride and terpene against herpes viruses was examined.
  • herpes viruses belong to the enveloped type having a lipid membrane.
  • Test Example 4-1 ⁇ Preparation of test solution as antiviral composition> (Test Example 4-1) 0.3 g of cetylpyridinium chloride, 0.1 g of glycyrrhizin stabilized with 4-tert-butylcatechol, and 10 ml of ethanol were diluted with sterilized ultrapure water to a total weight of 100 g. This was used as the test solution of the antiviral composition of Test Example 4-1 in an anti-herpes virus test.
  • Test Example 4-2 A test solution of Test Example 4-2 was prepared in the same manner as in Test Example 4-1, except that the amount of cetylpyridinium chloride was 0.05 g.
  • Comparative Example 4-1 In Comparative Example 4-1, a test solution not containing terpene was prepared. 0.3 g of cetylpyridinium chloride and 10 ml of ethanol were diluted with sterilized ultrapure water to a total volume of 100 g to prepare the test solution of Comparative Example 4-1.
  • Control 4 Sterile ultrapure water alone was used as the test liquid for Control 4.
  • ⁇ Anti-herpes virus test; measurement of infectious titer> Anti-herpes virus tests were carried out on each of the test solutions of Test Examples 4-1 to 4-2, Comparative Example 4-1, and Control 4.
  • the anti-herpes virus tests were carried out to measure the virucidal activity against herpes virus (KOS strain) in the same manner as the anti-viral test against influenza A virus. The results are shown in Figure 4.
  • the infectious titer of the test solution of Control 4 is shown by the dotted line.
  • Example 5 In Example 5, the antiviral effect of a test solution containing cetylpyridinium chloride and terpene against feline calicivirus was examined. Feline calicivirus is different from influenza virus and herpes virus in that it is a non-enveloped virus that does not have a lipid membrane.
  • Test Example 5-1 ⁇ Preparation of test solution as antiviral composition> (Test Example 5-1) 0.3 g of cetylpyridinium chloride, 0.1 g of thymol stabilized with 4-tert-butylcatechol, and 10 ml of ethanol were diluted with sterilized ultrapure water to a total weight of 100 g. This was used as a test solution of the antiviral composition of Test Example 5-1 in an anti-feline calicivirus test.
  • Test Example 5-2 A test solution of Test Example 5-2 was prepared in the same manner as in Test Example 5-1, except that thymol was replaced with glycyrrhizin.
  • Test Example 5-3 A test solution of Test Example 5-3 was prepared in the same manner as in Test Example 5-1, except that the amount of cetylpyridinium chloride was 0.05 g.
  • Test Example 5-4 The test solution of Test Example 5-4 was prepared in the same manner as in Test Example 5-1, except that benzalkonium chloride (BKC) was used instead of cetylpyridinium chloride.
  • BKC benzalkonium chloride
  • Benzalkonium chloride like cetylpyridinium chloride, is a compound belonging to the quaternary ammonium salts.
  • Comparative Example 5-1 was prepared as a test solution not containing terpene. 0.3 g of cetylpyridinium chloride and 10 ml of ethanol were diluted with sterilized ultrapure water to a total volume of 100 g to prepare the test solution of Comparative Example 5-1.
  • Example 6 The antiviral effect of a test solution containing cetylpyridinium chloride and terpene against adenovirus was examined in Example 6.
  • Adenovirus like feline calicivirus, belongs to the non-enveloped type that does not have a lipid membrane.
  • Test Example 6-1 ⁇ Preparation of test solution as antiviral composition> (Test Example 6-1) 0.3 g of cetylpyridinium chloride, 0.1 g of glycyrrhizin stabilized with 4-tert-butylcatechol, and 10 ml of ethanol were diluted with sterilized ultrapure water to a total weight of 100 g. This was used as the test solution of the antiviral composition of Test Example 6-1 in an anti-adenovirus test.
  • Test Example 6-2 A test solution of Test Example 6-2 was prepared in the same manner as in Test Example 6-1, except that the amount of cetylpyridinium chloride was 0.05 g.
  • Comparative Example 6-1 Comparative Example 6-1 was prepared as a test solution not containing terpene. 0.3 g of cetylpyridinium chloride and 10 ml of ethanol were diluted with sterilized ultrapure water to a total volume of 100 g to prepare the test solution of Comparative Example 6-1.
  • Control 6 Sterile ultrapure water alone was used as the test liquid for Control 6.
  • Example 7 In Example 7, the antiviral effect against influenza A virus of a test solution containing benzalkonium chloride (BKC), which belongs to a quaternary ammonium salt, and a terpene instead of cetylpyridinium chloride was examined.
  • BKC benzalkonium chloride
  • Test Example 7-1 0.3 g of benzalkonium chloride, 0.1 g of thymol stabilized with 4-tert-butylcatechol, and 10 ml of ethanol were diluted with sterilized ultrapure water to a total weight of 100 g. This was used as the test solution of the antiviral composition of Test Example 7-1 in an anti-type A influenza virus test.
  • Test Example 7-2 A test solution for Test Example 7-2 was prepared in the same manner as in Test Example 7-1, except that thymol was replaced with glycyrrhizin.
  • Test Example 7-3 A test solution of Test Example 7-3 was prepared in the same manner as in Test Example 7-1, except that the amount of benzalkonium chloride was 0.05 g.
  • Comparative Example 7-1 a test solution not containing terpene was prepared. 0.3 g of benzalkonium chloride and 10 ml of ethanol were diluted with sterilized ultrapure water to a total volume of 100 g to prepare the test solution of Comparative Example 7-1.
  • Comparative Example 7-2 A test solution of Comparative Example 7-2 was prepared in the same manner as in Comparative Example 7-1, except that the amount of benzalkonium chloride was 0.05 g.
  • Control 7 Sterile ultrapure water alone was used as the test liquid for Control 7. ⁇ Anti-type A influenza virus test; measurement of infectious titer> For each of the test solutions of Test Examples 7-1 to 7-3, Comparative Examples 7-1 to 7-2, and Control 7, an antiviral test against influenza A virus was carried out in the same manner as in Example 1. The results are shown in Figure 7. In Figure 7, the infectious titer of the test solution of Control 7 is shown by the dotted line.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La composition anti-virus de la grippe pour la gorge contient en tant que principes actifs un sel d'ammonium quaternaire et au moins un élément choisi parmi l'isoprène, le géraniol, le menthol, le limonène, le thymol, le cinéole, le bisabolol, le bornéol, le camphre et la glycyrrhizine.
PCT/JP2023/045484 2022-12-22 2023-12-19 Composition contre le virus de la grippe pour la gorge et agent anti-virus de la grippe pour la gorge WO2024135675A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-205412 2022-12-22
JP2022205412 2022-12-22

Publications (1)

Publication Number Publication Date
WO2024135675A1 true WO2024135675A1 (fr) 2024-06-27

Family

ID=91588562

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/045484 WO2024135675A1 (fr) 2022-12-22 2023-12-19 Composition contre le virus de la grippe pour la gorge et agent anti-virus de la grippe pour la gorge

Country Status (1)

Country Link
WO (1) WO2024135675A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513959A (ja) * 2003-12-10 2007-05-31 エスディー ファーマシューティカルズ インコーポレイティッド 抗ウイルス性薬学的組成物
JP2011079800A (ja) * 2009-10-09 2011-04-21 Kitasato Institute 抗インフルエンザウイルス剤
JP2022185721A (ja) * 2021-06-03 2022-12-15 日油株式会社 咽喉用組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513959A (ja) * 2003-12-10 2007-05-31 エスディー ファーマシューティカルズ インコーポレイティッド 抗ウイルス性薬学的組成物
JP2011079800A (ja) * 2009-10-09 2011-04-21 Kitasato Institute 抗インフルエンザウイルス剤
JP2022185721A (ja) * 2021-06-03 2022-12-15 日油株式会社 咽喉用組成物

Similar Documents

Publication Publication Date Title
CA2997312C (fr) Compositions de soin buccal renfermant un acide amine, des sources d'ionde zinc melangees et un systeme d'epaississant cellulose/polysaccharide
AU2013277105B2 (en) Mouth rinse emulsions
EP2672828B1 (fr) Composition antimicrobienne
JP2013506650A (ja) サニタイジング組成物
CN105592892A (zh) 包含没食子酸酯和没食子酸酰胺的组合物
JP4261744B2 (ja) 口腔用組成物
WO2021217324A1 (fr) Composition désinfectante, son procédé de préparation et son utilisation
JP4384717B2 (ja) 抗ウイルス剤
WO2024135675A1 (fr) Composition contre le virus de la grippe pour la gorge et agent anti-virus de la grippe pour la gorge
JP2011093835A (ja) 皮膚外用剤
ES2558252T3 (es) Composición antimicrobiana
JP2019006752A (ja) 口腔用組成物
JP2004256437A (ja) 抗菌剤及び抗菌性組成物
JP4803889B2 (ja) 非水系練歯磨剤
JP6489736B2 (ja) 低収斂性組成物
JP2015030701A (ja) 抗菌性口腔用組成物
JP2018052836A (ja) 外用組成物
JP6599515B2 (ja) 収斂用組成物
JP7175467B2 (ja) ノロウイルスおよびその代替ウイルスに対する抗ウイルス剤および抗ウイルス組成物
JP7330692B2 (ja) 口腔用組成物
JP7409775B2 (ja) 低収斂性組成物
Sucgang et al. Formulation Of Wet Wipes With Essential Oils Of Oregano (Origanum Vulgare), Lemongrass (Cymbopogon Citratus), And Peppermint (Mentha Piperita) Acting As Humectant Actives, Fragrance, And Anti-Viral Agents
TWI363621B (en) Antiviral composition
CN116157111A (zh) 保湿的抗菌组合物
CN118414157A (zh) 用于预防和/或减少病毒感染的组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23907035

Country of ref document: EP

Kind code of ref document: A1